BETTERLIFE PHARMA INC - BETRF STOCK NEWS

BetterLife Pharma Inc. (CSE: BETR, OTCQB: BETRF) has released positive preclinical data confirming the anti-depressant activity of its lead compound, 2-bromo-LSD (BETR-001). The research, conducted in collaboration with Carleton University, indicates BETR-001 significantly reduces depressive-like behavior in mice without affecting locomotion. This second-generation LSD derivative is designed to provide therapeutic effects without psychedelic side effects. BetterLife's innovative approach includes a synthesis patent that streamlines regulatory processes, positioning BETR-001 as a promising treatment for depression and other mental disorders.

BetterLife Pharma Inc. has announced positive pharmacokinetic data for its lead compound BETR-001 (2-bromo-LSD), confirming its bioavailability in the brain and plasma of treated mice. The study demonstrated that BETR-001 is non-hallucinogenic and achieves therapeutic levels, supporting its potential use in treating major depression and cluster headaches. Key findings include rapid appearance in plasma and brain within 10 minutes, sustained detection for up to 8 hours, and a half-life of approximately 1.5 hours. This data is crucial for BETR-001's IND application.

BetterLife Pharma has announced positive results from a preclinical study of its compound, BETR-001, in rat neurons. This non-hallucinogenic derivative of LSD demonstrated enhanced structural complexity in neurons, suggesting potential antidepressant effects. The study indicates BETR-001 promotes neural plasticity better than ketamine, supporting its therapeutic prospects for depression. The CEO highlights the compound's promise without causing hallucinations. BetterLife is focused on developing treatments for neuropsychological disorders through BETR-001 and another compound, BETR-002.

BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF) has received a favorable written response from the FDA regarding its pre-IND application for BETR-001, a non-hallucinogenic derivative of LSD aimed at treating major depressive disorder (MDD). The FDA's guidance supports BetterLife's program for BETR-001, enabling IND-enabling toxicology studies and clinical trial preparations. The Company plans to initiate human clinical trials for BETR-001 in the U.S. by Q3 2022, emphasizing its unique therapeutic potential for psychiatric disorders.

BetterLife Pharma reported positive results from an oral bioavailability and food-effect pharmacokinetic study on BETR-001 (2-bromo-LSD) in beagle dogs. Key findings include:

• Oral bioavailability of BETR-001 was around 61% for fasted and 63% for fed states.
• No significant difference in bioavailability based on feeding status.
• The drug reached peak concentration at 0.5 hours and remained detectable for up to 8 hours.

These results support the therapeutic potential of BETR-001 and bolster plans for filing its IND application with the FDA, aiming to initiate human trials in H2 2022.

BetterLife Pharma Inc. announced the appointment of Dr. Eleanor Fish to the Order of Canada for her significant contributions to immunology. Dr. Fish, a member of BetterLife’s Advisory Board, has made pivotal advancements in using interferon-alpha for disease treatment. This honor highlights her role as a Principal Investigator in a Phase 2 clinical trial for inhaled interferon-alpha2b against COVID-19 at Pontificia Universidad Católica de Chile. The Company expresses pride in Dr. Fish's achievements as it continues its commitment to developing treatments for mental disorders.

BetterLife Pharma Inc. announced a non-brokered financing of up to US$5.0 million through its subsidiary, Altum Pharmaceuticals Inc., with an investor group. The financing will be conducted in tranches starting January 2022. Once completed, the investor group will own approximately 12.5% of Altum's shares. CEO Dr. Ahmad Doroudian highlighted the funding's importance for advancing Altum's pre-clinical and clinical programs aimed at COVID-19 treatments. Additionally, a special committee is exploring strategic options, including a potential spin-off and listing of Altum on a national exchange in the U.S.

BetterLife Pharma Inc. announced positive results for its lead compound, TD-0148A, indicating anti-depressant properties in animal models. This innovative LSD derivative aims to treat major depressive disorder (MDD) without psychedelic effects. The study demonstrated significant behavioral improvements in chronically stressed female mice. BetterLife is advancing TD-0148A towards U.S. IND application, addressing the urgent need for new antidepressants amid rising resistance to current treatments. The global market for depression drugs is projected to reach nearly $25 billion by 2030.